Literature DB >> 12538159

Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival.

Thomas C Mitchell1, T Kent Teague, David A Hildeman, Jeremy Bender, William A Rees, Ross M Kedl, Brad Swanson, John W Kappler, Philippa Marrack.   

Abstract

A set of signals separate from those needed for T cell activation and clonal expansion acts to sustain a T cell response once it has begun. Immunologic adjuvants can initiate these signals in a process we designate adjuvant-induced survival (AIS). Here, the natural adjuvant LPS was used in a super-antigen model of AIS to understand which factors are needed to sustain T cell survival after activation. Flow cytometric stains for antiapoptotic Bcl-2 and Bcl-xL showed that neither factor was well correlated with AIS, although both were increased transiently upon T cell activation. T cells protected via AIS showed no increased ability to resist death caused by reactive oxygen species, and cellular division was not accelerated as might be expected if AIS were to operate through co-stimulatory pathways. Finally, microarray analyses were performed that showed increased expression of Bcl-3, an NFkappaB/IkappaB factor, was correlated with AIS. It is proposed that T cell survival during productive immune responses occurs by successive activities of Bcl-2, Bcl-xL and Bcl-3, with Bcl-3 requiring innate immune responses to adjuvants for its expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12538159     DOI: 10.1111/j.1749-6632.2002.tb05946.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Toll-like receptor ligands directly promote activated CD4+ T cell survival.

Authors:  Andrew E Gelman; Jidong Zhang; Yongwon Choi; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Authors:  Paula M Chilton; Thomas C Mitchell
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 3.  NF-kappaB pathways in the immune system: control of the germinal center reaction.

Authors:  Christine A Goetz; Albert S Baldwin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

4.  Notch controls the magnitude of T helper cell responses by promoting cellular longevity.

Authors:  Christina Helbig; Rebecca Gentek; Ronald A Backer; Yevan de Souza; Ingrid A M Derks; Eric Eldering; Koen Wagner; Dragana Jankovic; Thomas Gridley; Perry D Moerland; Richard A Flavell; Derk Amsen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  A role for the IkappaB family member Bcl-3 in the control of central immunologic tolerance.

Authors:  Xiaoren Zhang; Hongshan Wang; Estefania Claudio; Keith Brown; Ulrich Siebenlist
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

6.  Mapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor κB (NF-κB) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.

Authors:  Patricia E Collins; Gianluca Grassia; Amy Colleran; Patrick A Kiely; Armando Ialenti; Pasquale Maffia; Ruaidhrí J Carmody
Journal:  J Biol Chem       Date:  2015-04-28       Impact factor: 5.157

Review 7.  Role of Bcl-3 in solid tumors.

Authors:  Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  Mol Cancer       Date:  2011-12-23       Impact factor: 27.401

8.  TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Authors:  Siva K Gandhapudi; Paula M Chilton; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

9.  Transgenic Bcl-3 slows T cell proliferation.

Authors:  Michael F J Bassetti; Janice White; John W Kappler; Philippa Marrack
Journal:  Int Immunol       Date:  2009-02-10       Impact factor: 4.823

10.  An orally active immune adjuvant prepared from cones of Pinus sylvestris, enhances the proliferative phase of a primary T cell response.

Authors:  William Guy Bradley; Katharine Nichole Holm; Akiko Tanaka
Journal:  BMC Complement Altern Med       Date:  2014-05-22       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.